Abstract
Uveal melanoma (UM) is the most frequent intraocular tumor in adults with an annual incidence of about 6/1.000.000. Despite successful treatment of the primary tumor in most cases, approximately 50% of patients die from metastases within 15 years after treatment. This proportion has remained constant during the last decades.
Various clinical and histopathological parameters have been found to be associated with metastatic progression of uveal melanoma. Cytogenetic analysis has revealed that loss of one copy of chromosome 3 (monosomy 3), which is present in about half of all UMs is associated with poor prognosis. In fact, this is one of the most reliable prognostic markers and is superior to all clinical markers. Consequently, monosomy 3 testing is widely used in clinical routine in patients with uveal melanoma.
In recent years a UM classification model has gained acceptance, according to which UM is not a uniform entity but can be divided in at least two major classes. The strongest evidence for this model comes from global gene expression studies. Unsupervised data analysis of global expression data supports a highly robust class assignment of tumors. These classes are congruent with the chromosome 3 status and the metastatic potential of the tumor. Therefore, tumor classification by gene expression profiling is an alternative approach for predictive testing of patients. In this chapter we will describe the prognostic markers and the different diagnostic settings in more detail. Finally we will elaborate on the strength and weaknesses of these methods in the setting of routine testing of patients.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Egan KM, Seddon JM, Glynn RJ, Gragoudas ES, Albert DM (1988) Epidemiologic aspects of uveal melanoma. Surv Ophthalmol 32(4):239–251
Lommatzsch PK (1986) Results after beta-irradiation (106Ru/106Rh) of choroidal melanomas: 20 years’ experience. Br J Ophthalmol 70(11):844–851
Kujala E, Makitie T, Kivela T (2003) Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci 44(11):4651–4659
Diener-West M, Reynolds SM, Agugliaro DJ, Caldwell R, Cumming K, Earle JD, Hawkins BS, Hayman JA, Jaiyesimi I, Jampol LM, Kirkwood JM, Koh WJ, Robertson DM, Shaw JM, Straatsma BR, Thoma J (2005) Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. Arch Ophthalmol 123(12):1639–1643. doi: 123/12/1639[pii]10.1001/archopht.123.12.1639
Schmittel A, Bechrakis NE, Martus P, Mutlu D, Scheibenbogen C, Bornfeld N, Foerster MH, Thiel E, Keilholz U (2004) Independent prognostic factors for distant metastases and survival in patients with primary uveal melanoma. Eur J Cancer 40(16):2389–2395. doi: S0959-8049(04)00529-5[pii]10.1016/j.ejca.2004.06.028
Kath R, Hayungs J, Bornfeld N, Sauerwein W, Hoffken K, Seeber S (1993) Prognosis and treatment of disseminated uveal melanoma. Cancer 72(7):2219–2223
Prescher G, Bornfeld N, Becher R (1990) Nonrandom chromosomal abnormalities in primary uveal melanoma. J Natl Cancer Inst 82(22):1765–1769
Sisley K, Cottam DW, Rennie IG, Parsons MA, Potter AM, Potter CW, Rees RC (1992) Non-random abnormalities of chromosomes 3, 6, and 8 associated with posterior uveal melanoma. Genes Chromosomes Cancer 5(3):197–200
White VA, Chambers JD, Courtright PD, Chang WY, Horsman DE (1998) Correlation of cytogenetic abnormalities with the outcome of patients with uveal melanoma. Cancer 83(2):354–359. doi:10.1002/(SICI)1097-0142(19980715)83:2<354::AID-CNCR20>3.0.CO;2-R [pii]
Speicher MR, Prescher G, du Manoir S, Jauch A, Horsthemke B, Bornfeld N, Becher R, Cremer T (1994) Chromosomal gains and losses in uveal melanomas detected by comparative genomic hybridization. Cancer Res 54(14):3817–3823
Prescher G, Bornfeld N, Hirche H, Horsthemke B, Jockel KH, Becher R (1996) Prognostic implications of monosomy 3 in uveal melanoma. Lancet 347(9010):1222–1225
Van Raamsdonk CD, Griewank KG, Crosby MB, Garrido MC, Vemula S, Wiesner T, Obenauf AC, Wackernagel W, Green G, Bouvier N, Sozen MM, Baimukanova G, Roy R, Heguy A, Dolgalev I, Khanin R, Busam K, Speicher MR, O’Brien J, Bastian BC (2010) Mutations in GNA11 in uveal melanoma. N Engl J Med 363(23):2191–2199. doi: 10.1056/NEJMoa1000584
Harbour JW (2012) The genetics of uveal melanoma: an emerging framework for targeted therapy. Pigment Cell Melanoma Res 25(2):171–181. doi: 10.1111/j.1755-148X.2012.00979.x
Wiesner T, Obenauf AC, Murali R, Fried I, Griewank KG, Ulz P, Windpassinger C, Wackernagel W, Loy S, Wolf I, Viale A, Lash AE, Pirun M, Socci ND, Rutten A, Palmedo G, Abramson D, Offit K, Ott A, Becker JC, Cerroni L, Kutzner H, Bastian BC, Speicher MR (2011) Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet 43(10):1018–1021. doi: 10.1038/ng.910ng.910[pii]
Abdel-Rahman MH, Pilarski R, Cebulla CM, Massengill JB, Christopher BN, Boru G, Hovland P, Davidorf FH (2011) Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. J Med Genet. doi: jmedgenet-2011-100156[pii]10.1136/jmedgenet-2011-100156
McLean IW, Foster WD, Zimmerman LE (1982) Uveal melanoma: location, size, cell type, and enucleation as risk factors in metastasis. Hum Pathol 13(2):123–132
Parrella P, Sidransky D, Merbs SL (1999) Allelotype of posterior uveal melanoma: implications for a bifurcated tumor progression pathway. Cancer Res 59(13):3032–3037
Damato B, Dopierala JA, Coupland SE (2010) Genotypic profiling of 452 choroidal melanomas with multiplex ligation-dependent probe amplification. Clin Cancer Res 16(24):6083–6092. doi: 1078-0432.CCR-10-2076[pii]10.1158/1078-0432.CCR-10-2076
Damato B, Coupland SE (2009) Translating uveal melanoma cytogenetics into clinical care. Arch Ophthalmol 127(4):423–429. doi: 127/4/423[pii]10.1001/archophthalmol.2009.40
Onken MD, Worley LA, Ehlers JP, Harbour JW (2004) Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res 64(20):7205–7209
Tschentscher F, Hüsing J, Hölter T, Kruse E, Dresen IG, Jöckel KH, Anastassiou G, Schilling H, Bornfeld N, Horsthemke B, Lohmann DR, Zeschnigk M (2003) Tumor classification based on gene expression profiling shows that uveal melanomas with and without monosomy 3 represent two distinct entities. Cancer Res 63(10):2578–2584
Neumann LC, Weinhäusel A, Thomas S, Horsthemke B, Lohmann DR, Zeschnigk M (2011) EFS shows biallelic methylation in uveal melanoma with poor prognosis as well as tissue-specific methylation. BMC Cancer 11:380. doi: 1471-2407-11-380[pii]10.1186/1471-2407-11-380
Callejo SA, Dopierala J, Coupland SE, Damato B (2011) Sudden growth of a choroidal melanoma and multiplex ligation-dependent probe amplification findings suggesting late transformation to monosomy 3 type. Arch Ophthalmol 129(7):958–960. doi: 129/7/958[pii]10.1001/archophthalmol.2011.181
Beran TM, McCannel TA, Stanton AL, Straatsma BR, Burgess BL (2009) Reactions to and desire for prognostic testing in choroidal melanoma patients. J Genet Couns 18(3):265–274. doi: 10.1007/s10897-009-9223-2
Seddon JM, Albert DM, Lavin PT, Robinson N (1983) A prognostic factor study of disease-free interval and survival following enucleation for uveal melanoma. Arch Ophthalmol 101(12):1894–1899
Singh AD, Shields CL, Shields JA (2001) Prognostic factors in uveal melanoma. Melanoma Res 11(3):255–263
Mooy CM, De Jong PT (1996) Prognostic parameters in uveal melanoma: a review. Surv Ophthalmol 41(3):215–228. doi: S0039-6257(96)80024-5[pii]
Thomas S, Pütter C, Weber S, Bornfeld N, Lohmann DR, Zeschnigk M (2012) Prognostic significance of chromosome 3 alterations determined by microsatellite analysis in uveal melanoma: a long-term follow-up study. Br J Cancer 106(6):1171–1176. doi: 10.1038/bjc.2012.54bjc201254[pii]
Damato B, Coupland SE (2009) A reappraisal of the significance of largest basal diameter of posterior uveal melanoma. Eye (Lond) 23(12):2152–2160; quiz 2161–2152. doi: eye2009235[pii]10.1038/eye.2009.235-cme
Folberg R, Rummelt V, Parys-Van Ginderdeuren R, Hwang T, Woolson RF, Pe’er J, Gruman LM (1993) The prognostic value of tumor blood vessel morphology in primary uveal melanoma. Ophthalmology 100(9):1389–1398
Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LM, Pe’er J, Trent JM, Meltzer PS, Hendrix MJ (1999) Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 155(3):739–752. doi: S0002-9440(10)65173-5[pii]10.1016/S0002-9440(10)65173-5
Barak V, Frenkel S, Kalickman I, Maniotis AJ, Folberg R, Pe’er J (2007) Serum markers to detect metastatic uveal melanoma. Anticancer Res 27(4A):1897–1900
Scholes AG, Damato BE, Nunn J, Hiscott P, Grierson I, Field JK (2003) Monosomy 3 in uveal melanoma: correlation with clinical and histologic predictors of survival. Invest Ophthalmol Vis Sci 44(3):1008–1011
Sisley K, Rennie IG, Parsons MA, Jacques R, Hammond DW, Bell SM, Potter AM, Rees RC (1997) Abnormalities of chromosomes 3 and 8 in posterior uveal melanoma correlate with prognosis. Genes Chromosomes Cancer 19(1):22–28
Harbour JW, Onken MD, Roberson ED, Duan S, Cao L, Worley LA, Council ML, Matatall KA, Helms C, Bowcock AM (2010) Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 330(6009):1410–1413. doi: science.1194472[pii]10.1126/science.1194472
Petrausch U, Martus P, Tonnies H, Bechrakis NE, Lenze D, Wansel S, Hummel M, Bornfeld N, Thiel E, Foerster MH, Keilholz U (2008) Significance of gene expression analysis in uveal melanoma in comparison to standard risk factors for risk assessment of subsequent metastases. Eye (Lond) 22(8):997–1007. doi: 6702779[pii]10.1038/sj.eye.6702779
Onken MD, Worley LA, Tuscan MD, Harbour JW (2010) An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma. J Mol Diagn 12(4):461–468. doi: S1525-1578(10)60086-4[pii]10.2353/jmoldx.2010.090220
Onken MD, Worley LA, Davila RM, Char DH, Harbour JW (2006) Prognostic testing in uveal melanoma by transcriptomic profiling of fine needle biopsy specimens. J Mol Diagn 8(5):567–573. doi: S1525-1578(10)60346-7[pii]10.2353/jmoldx.2006.060077
Sisley K, Rennie IG, Cottam DW, Potter AM, Potter CW, Rees RC (1990) Cytogenetic findings in six posterior uveal melanomas: involvement of chromosomes 3, 6, and 8. Genes Chromosomes Cancer 2(3):205–209
Lake SL, Coupland SE, Taktak AF, Damato BE (2010) Whole-genome microarray detects deletions and loss of heterozygosity of chromosome 3 occurring exclusively in metastasizing uveal melanoma. Invest Ophthalmol Vis Sci 51(10):4884–4891. doi: iovs.09-5083[pii]10.1167/iovs.09-5083
Trolet J, Hupe P, Huon I, Lebigot I, Decraene C, Delattre O, Sastre-Garau X, Saule S, Thiery JP, Plancher C, Asselain B, Desjardins L, Mariani P, Piperno-Neumann S, Barillot E, Couturier J (2009) Genomic profiling and identification of high-risk uveal melanoma by array CGH analysis of primary tumors and liver metastases. Invest Ophthalmol Vis Sci 50(6):2572–2580. doi: iovs.08-2296[pii]10.1167/iovs.08-2296
van den Bosch T, van Beek J, Vaarwater J, Verdijk RM, Naus NC, Paridaens D, De Klein A, Kilic E (2012) Higher percentage of FISH-determined monosomy 3 and 8q gain in uveal melanoma cells relate to poor prognosis and shorter disease free interval. Invest Ophthalmol Vis Sci. doi: iovs.11-8697[pii]10.1167/iovs.11-8697
Damato B, Duke C, Coupland SE, Hiscott P, Smith PA, Campbell I, Douglas A, Howard P (2007) Cytogenetics of uveal melanoma: a 7-year clinical experience. Ophthalmology 114(10):1925–1931. doi: S0161-6420(07)00663-X[pii]10.1016/j.ophtha.2007.06.012
Patel KA, Edmondson ND, Talbot F, Parsons MA, Rennie IG, Sisley K (2001) Prediction of prognosis in patients with uveal melanoma using fluorescence in situ hybridisation. Br J Ophthalmol 85(12):1440–1444
Tschentscher F, Prescher G, Zeschnigk M, Horsthemke B, Lohmann DR (2000) Identification of chromosomes 3, 6, and 8 aberrations in uveal melanoma by microsatellite analysis in comparison to comparative genomic hybridization. Cancer Genet Cytogenet 122(1):13–17. doi: S0165-4608(00)00266-1[pii]
Shields CL, Ganguly A, Bianciotto CG, Turaka K, Tavallali A, Shields JA (2011) Prognosis of uveal melanoma in 500 cases using genetic testing of fine-needle aspiration biopsy specimens. Ophthalmology 118(2):396–401. doi: S0161-6420(10)00597-X[pii]10.1016/j.ophtha.2010.05.023
Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G (2002) Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 30(12):e57
Eisen MB, Spellman PT, Brown PO, Botstein D (1998) Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 95(25):14863–14868
Ringner M (2008) What is principal component analysis? Nat Biotechnol 26(3):303–304. doi: nbt0308-303[pii]10.1038/nbt0308-303
Abdel-Rahman MH, Christopher BN, Faramawi MF, Said-Ahmed K, Cole C, McFaddin A, Ray-Chaudhury A, Heerema N, Davidorf FH (2011) Frequency, molecular pathology and potential clinical significance of partial chromosome 3 aberrations in uveal melanoma. Mod Pathol. doi: modpathol201151[pii]10.1038/modpathol.2011.51
Damato B, Eleuteri A, Fisher AC, Coupland SE, Taktak AF (2008) Artificial neural networks estimating survival probability after treatment of choroidal melanoma. Ophthalmology 115(9):1598–1607. doi: S0161-6420(08)00099-7[pii]10.1016/j.ophtha.2008.01.032
Worley LA, Onken MD, Person E, Robirds D, Branson J, Char DH, Perry A, Harbour JW (2007) Transcriptomic versus chromosomal prognostic markers and clinical outcome in uveal melanoma. Clin Cancer Res 13(5):1466–1471. doi: 13/5/1466[pii]10.1158/1078-0432.CCR-06-2401
van Gils W, Kilic E, Bruggenwirth HT, Vaarwater J, Verbiest MM, Beverloo B, van Til-Berg ME, Paridaens D, Luyten GP, de Klein A (2008) Regional deletion and amplification on chromosome 6 in a uveal melanoma case without abnormalities on chromosomes 1p, 3 and 8. Melanoma Res 18(1):10–15. doi: 10.1097/CMR.0b013e3282f1d4d900008390-200802000-00002[pii]
Mensink HW, Vaarwater J, Kilic E, Naus NC, Mooy N, Luyten G, Bruggenwirth HT, Paridaens D, de Klein A (2009) Chromosome 3 intratumor heterogeneity in uveal melanoma. Invest Ophthalmol Vis Sci 50(2):500–504. doi: iovs.08-2279[pii]10.1167/iovs.08-2279
Maat W, van der Velden PA, Out-Luiting C, Plug M, Dirks-Mulder A, Jager MJ, Gruis NA (2007) Epigenetic inactivation of RASSF1a in uveal melanoma. Invest Ophthalmol Vis Sci 48(2):486–490. doi: 48/2/486[pii]10.1167/iovs.06-0781
Schoenfield L, Pettay J, Tubbs RR, Singh AD (2009) Variation of monosomy 3 status within uveal melanoma. Arch Pathol Lab Med 133(8):1219–1222. doi: 2008-0723-OAR1[pii]10.1043/1543-2165-133.8.1219
Lake SL, Damato BE, Dopierala J, Baudo MM, Taktak AF, Coupland SE (2011) Multiplex ligation-dependent probe amplification analysis of uveal melanoma with extraocular extension demonstrates heterogeneity of gross chromosomal abnormalities. Invest Ophthalmol Vis Sci 52(8):5559–5564. doi: iovs.10-6845[pii]10.1167/iovs.10-6845
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Zeschnigk, M., Lohmann, D.R. (2013). Prognostic Testing in Uveal Melanoma. In: Pfeffer, U. (eds) Cancer Genomics. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-5842-1_3
Download citation
DOI: https://doi.org/10.1007/978-94-007-5842-1_3
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-5841-4
Online ISBN: 978-94-007-5842-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)